Results 151 to 160 of about 2,136 (172)

Blastic Plasmacytoid Dendritic Cell Neoplasm

The American Journal of Dermatopathology, 2021
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy that frequently has cutaneous manifestations. The diagnosis can be a challenge because of its heterogenous clinical presentation, ranging from a brown or violaceous solitary nodule or patch to mixed, disseminated lesions.
Ather, Adnan, Priscilla R, Powell, Cecil Jordan, Staples, Bradley, Evanson, Palak K, Parekh   +4 more
openaire   +3 more sources

Blastic Plasmacytoid Dendritic Cell Neoplasm in Children

Hematology/Oncology Clinics of North America, 2020
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematological malignancy, derived from plasmacytoid dendritic cells. It mainly occurs in older adults, but has been reported across all age groups. Most patients present with skin lesions with or without marrow involvement and leukemic dissemination.
Yixian, Li, Victoria, Sun, Weili, Sun, Anna, Pawlowska   +3 more
openaire   +2 more sources

Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches [PDF]

British Journal of Haematology, 2016
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare haematological malignancy derived from the precursors of plamacytoid dendritic cells, with an aggressive clinical course and high frequency of cutaneous and bone marrow involvement ...
Livio Pagano, Caterina Giovanna Valentini, Sara Grammatico   +2 more
exaly   +2 more sources

Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm

Hematology/Oncology Clinics of North America, 2020
Tagraxofusp, a CD123-targeted immunotoxin, is the first FDA-approved treatment for patients 2 years and older with blastic plasmacytoid dendritic cell neoplasm (BPDCN). It has been shown to be safe and effective in treatment-naïve and previously treated adult patients, with high rates of successful bridging to hematopoietic stem cell transplantation ...
Danielle, Hammond, Naveen, Pemmaraju
openaire   +2 more sources

The lenalidomide/bortezomib/dexamethasone regimen for the treatment of blastic plasmacytoid dendritic cell neoplasm

Hematological Oncology, 2019
International audienceWe describe the use and value of a lenalidomide/bortezomib/dexamethasone regimen for the treatment of three patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN, a disease that lacks a consensus treatment).
Vincent Marmouset
exaly   +2 more sources

Blastic plasmacytoid dendritic cell neoplasm

Hematology Meeting Reports, 2009
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare haematological malignancy characterized by the clonal proliferation of immature or precursors of plasmacytoid dendritic cells (PDC), also known as professional type I interferon producing cells.1 This neoplasm was originally recognized in 19942 and the uncertainty regarding its histogenesis
F Facchetti, M Ungari, D Marocolo, S Lonardi, W Vermi   +4 more
openaire   +1 more source

Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: A case report and literature review

Journal of Oncology Pharmacy Practice, 2021
Yazan Samhouri, Salman Fazal
exaly  

More on Blastic Plasmacytoid Dendritic-Cell Neoplasms

New England Journal of Medicine, 2019
Jean-Baptiste, Micol, Sylvain, Pilorge, David, Ghez   +2 more
openaire   +4 more sources

<p>Tagraxofusp for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Brief Report on Emerging Data</p>

OncoTargets and Therapy, 2020
Guillaume Béziat, Loïc Ysebaert
exaly  

Role of tagraxofusp in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN)

Expert Opinion on Biological Therapy, 2020
Mansour Alfayez, Marina Konopleva, Naveen Pemmaraju   +2 more
exaly